Studio	Promotore	Data Parere Unico CE	Documenti
Studio di fase 3°, multicentrico, randomizzato, in doppio-cieco, controllato verso placebo per valutare l'efficacia e la sicurezza di canakinumab sulla sindrome di rilascio delle citochine in pazienti con polmonite indotta da COVID-19 (CAN-COVID)	Novartis Research and Development	06/05/2020	https://www.aifa.gov.it/documents/20142/1131319/CAN-COVID_documenti.zip
Studio clinico randomizzato controllato open label per valutare l'efficacia e la sicurezza dell'associazione di idrossiclorochina più azitromicina versus idrossiclorochina in pazienti affetti da polmonite da COVID-19 (AZI-RCT-COVID19)	Università del Piemonte Orientale (UPO)	04/05/2020	https://www.aifa.gov.it/documents/20142/1131319/AZI-RCT-COVID-19_documenti.zip
Studio di fase 2/3 in aperto, randomizzato, a due gruppi paralleli multicentrico per valutare l'efficacia e la sicurezza della somministrazione endovenosa di pamrevlumab, in confronto alla gestione clinica standard, in pazienti con infezione da SARS-CoV-2 (FivroCov)	UCSC -ROMA	05/05/2020	https://www.aifa.gov.it/documents/20142/1131319/FibroCov_documenti.zip
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Inpatients with COVID-19-General Type (HS216C17)	ASST FATEBENEFRATELLI SACCO	05/05/2020	https://www.aifa.gov.it/documents/20142/1131319/HS216C17_documenti.zip
Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 (the AMMURAVID trial)	Sociteà Italiana di Malattie Infettive e Tropicali (SIMIT)	01/05/2020	https://www.aifa.gov.it/documents/20142/1131319/AMMURAVID_documenti.zip
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection (XPORT-CoV-1001)	Karyopharm Therapeutics Inc	28/04/2020	https://www.aifa.gov.it/documents/20142/1131319/XPORT-CoV-1001_documenti.zip
Studio clinico di fase 3, randomizzato, in aperto, multicentrico volto a confrontare l'efficacia clinica e la sicurezza di Sarilumab per via endovenosa in aggiunta allo standard of care rispetto allo standard of care, nel trattamento di pazienti con polmonite severa da COVID-19. (ESCAPE)	INMI "L. Spallanzani" - Roma	28/04/2020	https://www.aifa.gov.it/documents/20142/1131319/ESCAPE_documenti.zip
PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19) - IRST 100.47	Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori – IRST IRCCS - Meldola	27/04/2020	https://www.aifa.gov.it/documents/20142/1131319/PROTECT_documenti.zip
Enoxaparina per la tromboprofilassi di pazienti ospedalizzati COVID-19 positivi: comparazione fra dosaggio di 40 mg in monosomministrazione versus 40 mg bigiornalieri. Un trial clinico randomizzato X-COVID	ASST Grande Ospedale Metropolitano Niguarda	22/04/2020	https://www.aifa.gov.it/documents/20142/1131319/X-COVID_documenti.zip
Pilot study on the use of sarilumab in patients with covid-19 infection (COVID-SARI)	ASST Fatebenefratelli Sacco	24/04/2020	https://www.aifa.gov.it/documents/20142/1131319/COVID-SARI_documenti.zip

Studio	Promotore	Data Parere Unico CE	Documenti
Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)	Università di Oxford (UK)	30/03/2020	https://www.aifa.gov.it/documents/20142/1131319/COP-COV_documenti.zip
BARICIVID-19 STUDY:MultiCentre, randomised, Phase IIa clinical trial evaluating efficacy and tolerability of Baricitinib as add-on treatment of patients with COVID-19 compared to standard therapy	Azienda Ospedaliera Universitaria Pisana	22/04/2020	https://www.aifa.gov.it/documents/20142/1131319/BARCIVID_documenti.zip
Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID19: a pilot phase II single-arm study, INHIXACOVID19	Università di Bologna	22/04/2020	https://www.aifa.gov.it/documents/20142/1131319/INHIXACOVID_documenti.zip
Colchicina per contrastare la risposta infiammatoria in corso di polmonite da COVID 19	AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA	20/04/2020	https://www.aifa.gov.it/documents/20142/1131319/ColCOVID_documenti.zip
Trattamento con COLchicina di pazienti affetti da COVID-19: uno studio pilota (COLVID-19)	Azienda Ospedaliera di Perugia	11/04/2020	https://www.aifa.gov.it/documents/20142/1131319/colchicina_Documenti.zip
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care	Organizzazione Mondiale della Sanità/Università di Verona	09/04/2020	https://www.aifa.gov.it/documents/20142/1131319/Solidarity_Documenti.zip
Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients (Hydro-Stop-COVID19 Trial)	ASUR-AV5 Ascoli Piceno	08/04/2020	https://www.aifa.gov.it/documents/20142/1131319/Hydro-Stop_Documenti.zip
A randomized, double-blind, placebocontrolled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe covid-19 pneumonia (Tocilizumab 2020-001154-22).	F. Hoffmann-La Roche Ltd	30/03/3020	https://www.aifa.gov.it/documents/20142/1131319/Tocilizumab_Documenti.zip
Uno studio randomizzato multicentrico in aperto per valutare l'efficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19 (RCT-TCZ-COVID-19).	Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia	27/03/2020	https://www.aifa.gov.it/documents/20142/1131319/RCT-TCZ-COVID19_documenti.zip
An adaptive phase 2/3, randomized, double-blind, placebocontrolled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 (Sarilumab COVID-19).	sanofi-aventis Recherche & Développement	26/03/2020	https://www.aifa.gov.it/documents/20142/1131319/Sarilumab_documenti.zip

Studio	Promotore	Data Parere Unico CE	Documenti
A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) monoclonal antibody, and anakinra, an interleukin-1(IL-1) receptor antagonist, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARSCoV-2 infection (Sobi.IMMUNO-101).	SOBI	25/03/2020	https://www.aifa.gov.it/documents/20142/1131319/Sobi.IMMUNO-101_documenti.zip
Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19).	Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale – Via M. Semmola 80131 Napoli	18/03/2020	https://www.aifa.gov.it/documents/20142/1131319/TOCIVID-19_documenti.zip
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment. (GS-US-540-5774 Study)	Gilead Sciences, Inc	11/03/2020	https://www.aifa.gov.it/documents/20142/1131319/GS-US-540-5774_documenti.zip
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19. (GS-US-540-5773 Study)	Gilead Sciences, Inc	11/03/2020	https://www.aifa.gov.it/documents/20142/1131319/GS-US-540-5773_documenti.zip